Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Sees Large Decrease in Short Interest

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totalling 3,750,000 shares, a decline of 67.6% from the December 15th total of 11,570,000 shares. Based on an average trading volume of 52,100,000 shares, the short-interest ratio is presently 0.1 days.

Conduit Pharmaceuticals Stock Performance

NASDAQ CDT traded down $0.03 during trading hours on Monday, hitting $0.09. 53,979,210 shares of the company traded hands, compared to its average volume of 254,589,047. The business’s 50-day moving average is $0.09 and its 200-day moving average is $0.16. Conduit Pharmaceuticals has a twelve month low of $0.05 and a twelve month high of $4.09.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.